Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2011

01.02.2011

Physicians’ perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey

verfasst von: Enrique Ginzburg, Franck Dujardin

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Decisions regarding choice of thromboprophylaxis in patients undergoing major orthopedic surgery are based on assessment of individual patient risk for thrombosis versus risk for bleeding. An international survey sought physician views on definitions and relative importance of different types of major bleeding. A random sample of physicians from five countries (100 physicians per country, mainly surgeons) completed an internet-based 13-question survey on perceptions, concerns, and relevance of bleeding associated with thromboprophylaxis in major orthopedic surgery. Over 80% of responders were concerned or very concerned about bleeding with >70% considering surgical-site bleeding as the most concerning, and relevant type and site for bleeding. Nearly 80% of responders considered surgical-site bleeding to increase patient length of hospital stay, and >70% noted that it complicates patient rehabilitation. After fatal bleeding, bleeding leading to re-operation was ranked as the most concerning type of major bleed. Less than half of responders reported closely reading the major-bleeding definitions in clinical study publications. Most responders favored anticoagulants that could offer a reduced bleeding risk and similar venous thromboembolism (VTE) prevention compared to current anticoagulants rather than a decrease in VTE and similar bleeding risk. There is a disconnect between the definitions of major bleeding that surgeons would apply to describe bleeding associated with VTE thromboprophylaxis, and those used in clinical studies reporting the safety profiles of newer anticoagulant agents. Misperceptions about the benefit-to-harm profiles of thromboprophylactic therapies may incorrectly inform treatment choices in patients at high risk for post-operative VTE.
Literatur
1.
Zurück zum Zitat Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edn). Chest 133(Suppl. 6):381S–453SCrossRefPubMed Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edn). Chest 133(Suppl. 6):381S–453SCrossRefPubMed
2.
Zurück zum Zitat Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775CrossRefPubMed Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775CrossRefPubMed
3.
Zurück zum Zitat Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39CrossRefPubMed Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39CrossRefPubMed
4.
Zurück zum Zitat Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786CrossRefPubMed Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786CrossRefPubMed
5.
Zurück zum Zitat Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 Investigators (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680CrossRefPubMed Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 Investigators (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680CrossRefPubMed
6.
Zurück zum Zitat Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, RE-MODEL Büller HR Study Group (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185CrossRefPubMed Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, RE-MODEL Büller HR Study Group (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185CrossRefPubMed
7.
Zurück zum Zitat Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR RE-NOVATE Study Group (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956CrossRefPubMed Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR RE-NOVATE Study Group (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956CrossRefPubMed
8.
Zurück zum Zitat RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1–9PubMed RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1–9PubMed
9.
Zurück zum Zitat Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594–604CrossRefPubMed Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594–604CrossRefPubMed
10.
Zurück zum Zitat Eichler HG, Abadie E, Raine JM, Salmonson T (2009) Safe drugs and the cost of good intentions. N Engl J Med 360:1378–1380CrossRefPubMed Eichler HG, Abadie E, Raine JM, Salmonson T (2009) Safe drugs and the cost of good intentions. N Engl J Med 360:1378–1380CrossRefPubMed
11.
Zurück zum Zitat Hull RD, Yusen RD, Bergqvist D (2009) State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 15:377–388CrossRefPubMed Hull RD, Yusen RD, Bergqvist D (2009) State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 15:377–388CrossRefPubMed
12.
Zurück zum Zitat Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest Physicians (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133(6 Suppl):257S–298SCrossRefPubMed Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest Physicians (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133(6 Suppl):257S–298SCrossRefPubMed
13.
Zurück zum Zitat Pitrou I, Boutron I, Ahmad N, Ravaud P (2009) Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 169:1756–1761CrossRefPubMed Pitrou I, Boutron I, Ahmad N, Ravaud P (2009) Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 169:1756–1761CrossRefPubMed
14.
Zurück zum Zitat Ioannidis JP (2009) Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 169:1737–1739CrossRefPubMed Ioannidis JP (2009) Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 169:1737–1739CrossRefPubMed
15.
Zurück zum Zitat Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202–204CrossRefPubMed Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202–204CrossRefPubMed
16.
Zurück zum Zitat Montserrat Vera-Llonch M, Hagiwara M, Oster G (2006) Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 117:569–577CrossRefPubMed Montserrat Vera-Llonch M, Hagiwara M, Oster G (2006) Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 117:569–577CrossRefPubMed
17.
Zurück zum Zitat Holzheimer RG (2004) Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH). Eur J Med Res 9:150–170PubMed Holzheimer RG (2004) Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH). Eur J Med Res 9:150–170PubMed
18.
Zurück zum Zitat Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA (2005) Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin 21:1085–1090CrossRefPubMed Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA (2005) Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin 21:1085–1090CrossRefPubMed
19.
Zurück zum Zitat Cullen G, Kelly E, Murray FE (2006) Patients’ knowledge of adverse reactions to current medications. Br J Clin Pharmacol 62:232–236CrossRefPubMed Cullen G, Kelly E, Murray FE (2006) Patients’ knowledge of adverse reactions to current medications. Br J Clin Pharmacol 62:232–236CrossRefPubMed
20.
Zurück zum Zitat Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR (2009) Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes 7:30CrossRefPubMed Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR (2009) Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes 7:30CrossRefPubMed
Metadaten
Titel
Physicians’ perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey
verfasst von
Enrique Ginzburg
Franck Dujardin
Publikationsdatum
01.02.2011
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2011
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-010-0498-9

Weitere Artikel der Ausgabe 2/2011

Journal of Thrombosis and Thrombolysis 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.